^
Association details:
| Biomarker: | NRAS Q61K |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | ASN007 (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
Published date:
07/21/2021
Excerpt:
ASN007 activity was also evaluated in four different human tumor xenograft mouse models harboring either KRAS or NRAS mutations: (1) HCT116, a colorectal adenocarcinoma cell line with a KRASG13D mutation; (2) Panc-1, a pancreatic adenocarcinoma model with a KRASG12D mutation; (3) MIA PaCa-2, a pancreatic adenocarcinoma model with a KRASG12C mutation; and (4) SK-N-AS, a neuroblastoma model with a NRASQ61K mutation. In all four models, ASN007 demonstrated strong antitumor efficacy...
DOI:
10.1016/j.xcrm.2021.100350
